Akiram Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$552K
- Investors
-
7
Akiram Therapeutics General Information
Description
Developer of radiopharmaceuticals designed for advancing radiotherapeutics to treat solid tumors. The company is focused on designing and developing novel radioactive cancer-targeting molecules and pharmaceuticals for diagnostics and therapy, helping doctors visualize and treat aggressive cancers.
Contact Information
Website
www.akiramtherapeutics.seCorporate Office
- Ihres väg 38
- 752 63 Uppsala
- Sweden
Corporate Office
- Ihres väg 38
- 752 63 Uppsala
- Sweden
Akiram Therapeutics Timeline
Akiram Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 24-Nov-2023 | $552K | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC | 12-Jan-2023 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC | 01-Jan-2022 | Completed | Pre-Clinical Trials |
Akiram Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Akiram Therapeutics Patents
Akiram Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023274919-A1 | Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers | Pending | 25-May-2022 | ||
| EP-4532019-A2 | Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers | Pending | 25-May-2022 | ||
| WO-2023227644-A3 | Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers | Inactive | 25-May-2022 | ||
| US-20250340662-A1 | Binding protein | Pending | 25-May-2022 | ||
| WO-2023227644-A2 | Binding protein | Inactive | 25-May-2022 | C07K16/2884 |
Akiram Therapeutics Signals
Akiram Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Erling Persson Family Foundation | Limited Partner | |||
| 3T Invest | Venture Capital | Minority | ||
| Linc (Sweden) | Venture Capital | Minority | ||
| Northislet | Growth/Expansion | Minority | ||
| Phase2Phase Biopharma | Venture Capital | Minority |
Akiram Therapeutics FAQs
-
When was Akiram Therapeutics founded?
Akiram Therapeutics was founded in 2021.
-
Where is Akiram Therapeutics headquartered?
Akiram Therapeutics is headquartered in Uppsala, Sweden.
-
What is the size of Akiram Therapeutics?
Akiram Therapeutics has 6 total employees.
-
What industry is Akiram Therapeutics in?
Akiram Therapeutics’s primary industry is Drug Discovery.
-
Is Akiram Therapeutics a private or public company?
Akiram Therapeutics is a Private company.
-
What is Akiram Therapeutics’s current revenue?
The current revenue for Akiram Therapeutics is .
-
How much funding has Akiram Therapeutics raised over time?
Akiram Therapeutics has raised $6.49M.
-
Who are Akiram Therapeutics’s investors?
Erling Persson Family Foundation, 3T Invest, Linc (Sweden), Northislet, and Phase2Phase Biopharma are 5 of 7 investors who have invested in Akiram Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process